SRR15030887
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- TNFA_SIGNALING_VIA_NFKB+0.350
- PROTEIN_SECRETION+0.340
- UV_RESPONSE_DN+0.340
- KRAS_SIGNALING_UP+0.320
- TGF_BETA_SIGNALING+0.320
- ANGIOGENESIS+0.290
- COMPLEMENT+0.270
- MITOTIC_SPINDLE+0.260
- HYPOXIA+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.460
- BILE_ACID_METABOLISM-0.290
- DNA_REPAIR-0.230
- KRAS_SIGNALING_DN-0.230
- XENOBIOTIC_METABOLISM-0.230
- FATTY_ACID_METABOLISM-0.220
- OXIDATIVE_PHOSPHORYLATION-0.220
- UV_RESPONSE_UP-0.190
- ADIPOGENESIS-0.180
- PEROXISOME-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290934 | — | — | 0.832 |
| 2 | 6a43f966-cb2b-47ee-b0f4-c269707daa88 | — | — | 0.822 |
| 3 | SJEPD030943_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.814 |
| 4 | TCGA-60-2704-01A-11R-2045-07 | — | cohortSQ1 | 0.813 |
| 5 | f5e6497a-ed39-408d-9034-a965baaafbf7 | — | — | 0.810 |
| 6 | DRR168609 | — | — | 0.796 |
| 7 | SRR15030893 | — | — | 0.793 |
| 8 | TCGA-86-8055-01A-11R-2241-07 | — | cohortA1 | 0.782 |
| 9 | TCGA-A7-A26G-01A-21R-A169-07 | — | D | 0.780 |
| 10 | SRR10900557 | — | — | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |